NasdaqGM:ACNT
NasdaqGM:ACNTMetals and Mining

Ascent Industries (ACNT) Losses Worsen; Deep Discount Reinforces Bearish Profitability Narrative

Ascent Industries (ACNT) has posted continued losses, with net income declining at an average rate of 16.3% per year over the past five years. Despite this persistent unprofitability and low earnings quality, the stock stands out for its value credentials: the current price-to-sales ratio is just 0.7x, notably below the US Metals and Mining industry average of 2.7x, and shares trade at $12.54, beneath the estimated fair value of $17.90. While ongoing losses and lack of visibility on future...
NYSE:SMG
NYSE:SMGChemicals

Scotts Miracle-Gro (SMG) One-Off $136.1M Loss Reinforces Debate Over Quality of Recent Profitability

Scotts Miracle-Gro (SMG) reported earnings that finally swung into profitability over the last year, with EPS growth now forecast at 12.58% per year. Despite this turnaround, the company’s earnings have been on a tough path, declining at an average annual rate of 45.6% over the past five years. Recent results were impacted by a $136.1 million one-off loss. Revenue growth is expected to lag behind the broader market at 1.9% per year. Shares look expensive at a 60.9x price-to-earnings ratio...
NYSE:BHR
NYSE:BHRHotel and Resort REITs

Braemar Hotels & Resorts (BHR): No Profit Margin Progress, Low Valuation Frames Investor Debate

Braemar Hotels & Resorts (BHR) remains unprofitable, with no improvement in its net profit margin over the last year. Over a five-year stretch, however, the company has steadily narrowed its losses at a rate of 7.3% per year. Revenue is forecast to grow at just 0.9% annually, compared to the broader US market’s projected 10.5% growth. In this operational context, BHR’s price-to-sales ratio of 0.2x stands out as especially low relative to both the industry and peers. The share price of $2.58...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Teva (TEVA) Discounted Valuation Reinforces Bull Case Despite Unprofitability and Slow Revenue Growth

Teva Pharmaceutical Industries (TEVA) is currently unprofitable, but the company has managed to trim its losses by 28.6% per year over the past five years. Revenue is forecast to grow at 2.8% per year, which is well below the US pharmaceutical market average of 10.5%. Earnings are expected to jump 19.73% annually, with the company projected to become profitable within three years. With shares trading at a significant discount compared to fair value and peers, the improving earnings outlook...
NYSE:ELAN
NYSE:ELANPharmaceuticals

Elanco Animal Health (ELAN): $606M One-Off Gain Raises Questions on Earnings Quality Versus Growth Hopes

Elanco Animal Health (ELAN) returned to profitability over the last year, with average annual earnings growth of 17.5% over the past five years. There is a dash of optimism as forecast earnings are projected to surge by 40.2% per year moving forward, far above the US market’s 16%. However, revenue growth is expected to lag at 4.4% annually versus the broader market’s 10.5%. The company’s recent $606.0 million one-off gain complicates the story by inflating margins for the period. These...
NYSE:JCI
NYSE:JCIBuilding

Johnson Controls (JCI): Profit Margin Jumps to 8.5%, Challenging Valuation Concerns

Johnson Controls International (JCI) posted a net profit margin of 8.5%, a significant jump from 5.9% last year, as earnings surged 75.6% over the past twelve months. While both revenue and earnings are projected to keep rising, with revenues at 4.8% and earnings at 7.7% per year, these growth rates are expected to trail the wider US market. Alongside these headline results, investors are weighing strong recent profit momentum against a relatively steep valuation premium in the sector. See...
NasdaqGS:PNFP
NasdaqGS:PNFPBanks

Assessing Pinnacle Financial Partners (PNFP) Valuation After Recent Modest Share Price Movement

Pinnacle Financial Partners (PNFP) shares have experienced modest movement this week, with the stock ticking up just under 1% over the last day but still down about 8% for the past month. Investors are watching for the company’s next catalyst. See our latest analysis for Pinnacle Financial Partners. Pinnacle Financial Partners has seen momentum fizzle in recent months, with the 1-year total shareholder return now sitting at a disappointing -29%. While the current share price has ticked up...
NYSE:LOAR
NYSE:LOARAerospace & Defense

Assessing Loar Holdings (LOAR) Valuation After Recent Share Price Dip

Loar Holdings (LOAR) shares have seen movement recently, which has caught the attention of investors trying to gauge what is next for the aerospace parts supplier. The company’s stock is navigating a patch of modest declines this month, with a recent dip of about 4% over the past month, sparking fresh conversation around its current valuation. See our latest analysis for Loar Holdings. This month’s 4.5% drop in Loar Holdings’ share price comes after a generally muted period, as the stock’s...
NasdaqGM:FHTX
NasdaqGM:FHTXBiotechs

Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Sets High Bar Despite Ongoing Losses

Foghorn Therapeutics (FHTX) reported ongoing losses, with net losses having increased at an average rate of 1.4% per year over the past five years. The company remains unprofitable, and consensus expects this trend to continue for at least the next three years. On the upside, revenue is forecast to surge by around 28.8% per year, far outpacing the 10.5% growth expected across the broader US market. With losses persisting but robust revenue growth anticipated, investors are left weighing the...
NYSE:CAT
NYSE:CATMachinery

How Record Sales and Backlogs at Caterpillar (CAT) Are Shaping Its Long-Term Investment Narrative

Caterpillar reported record third-quarter sales of US$17.64 billion and an all-time high order backlog of US$39.8 billion, leading management to raise both its full-year and fourth-quarter sales guidance in light of robust global demand across key segments. A unique driver behind the growth was a surge in orders from data center customers within the Energy & Transportation division, helping offset persistent tariff-related cost pressures and supporting analyst confidence in the company’s...
NYSE:OC
NYSE:OCBuilding

Owens Corning (OC) Profit Margin Falls Sharply, Challenging Bullish Efficiency and Growth Narratives

Owens Corning (OC) is forecasting annual earnings growth of 20.4%, outpacing the broader US market’s expected 16% per year, but revenue is set to rise by just 1.5% per year compared to the market’s 10.5%. Net profit margin dropped to 6% from 10.8% last year, with the most recent numbers impacted by a one-off $675 million loss. Investors are watching closely as the company now trades at a P/E of 13.2x, well below both the US Building industry average and its peers, and its current share price...
TSX:FM
TSX:FMMetals and Mining

First Quantum Minerals (TSX:FM): What Do Narrowed Guidance and Earnings Loss Mean for Valuation?

First Quantum Minerals (TSX:FM) released its third quarter earnings, reporting a net loss, whereas last year it had posted a profit. The company also narrowed its production guidance for copper, gold, and nickel. See our latest analysis for First Quantum Minerals. First Quantum Minerals has seen plenty of action this year. Following its recent earnings miss, ongoing challenges in copper and gold output, and tighter production guidance, the share price has still managed a solid year-to-date...
NasdaqGS:AVNW
NasdaqGS:AVNWCommunications

Aviat Networks (AVNW) Margin Miss Reinforces Concerns After $3.6M One-Off Loss

Aviat Networks (AVNW) posted a net profit margin of 0.3% for the most recent period, dipping from last year’s 2.6%, as a $3.6 million one-off loss weighed on results. While annual earnings have declined at a steep 55.2% rate over the past five years, the company is still profitable, and earnings are forecast to rebound sharply with 37.3% annual growth expected going forward. For investors, the stock’s low price-to-sales multiple and strong earnings growth outlook shape an interesting story...
NYSE:BF.B
NYSE:BF.BBeverage

What Do Recent Price Swings Signal for Brown-Forman’s True Value in 2025?

Thinking about whether Brown-Forman stock is a genuine bargain or just looks cheap on paper? You're not alone. It's a good time to take a closer look at what drives its current value. The stock has experienced a whirlwind of ups and downs lately, with a 1.0% gain over the last week but still down 33.2% for the past year. This has made investors wonder if change is in the air. Some of this volatility has been shaped by shifting industry dynamics and evolving consumer preferences, which have...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Assessing Exact Sciences After 20% Share Price Surge and Breakthrough Cancer Diagnostic News

Wondering if Exact Sciences stock is undervalued, overpriced, or poised for a breakout? You are not alone. With recent market shifts, there is plenty to discuss about whether now is the right time to buy. The share price has jumped 11.0% in just the past week and is up 20.8% over the last month, signaling both renewed interest and potential shifts in risk appetite among investors. Major headlines about Exact Sciences have highlighted the company's innovative work in cancer diagnostics,...
NasdaqGS:IEP
NasdaqGS:IEPIndustrials

Assessing Icahn Enterprises (IEP) Valuation Following Strong Net Income Growth in Recent Results

Icahn Enterprises (IEP) just released third quarter results, drawing attention for a surge in net income compared to last year, even as sales and revenue held steady. Investors are parsing what this means for future performance. See our latest analysis for Icahn Enterprises. Icahn Enterprises has seen a burst of momentum lately, with its share price climbing 8.9% in the past week and 7.0% over the last month. Still, when you zoom out, the one-year total shareholder return is down a steep...
TSXV:ASE
TSXV:ASEMetals and Mining

Asante Gold (TSXV:ASE): Exploring Valuation After Strong 1-Year Returns and Recent Share Price Pullback

Asante Gold (TSXV:ASE) has delivered some big moves for shareholders lately, and its 1-year return of 56% stands out in the turbulent gold sector. The stock's performance over the past month, however, shows a slight pullback. This has prompted investors to take a closer look at what might come next. See our latest analysis for Asante Gold. Momentum in Asante Gold’s share price has cooled slightly this month, with a 1-month share price return of -19.3%. This follows a stretch of rapid gains,...
TSX:PHX
TSX:PHXEnergy Services

PHX Energy (TSX:PHX) Margin Drops to 7.6% as One-Off Gain Distorts Profit Outlook

PHX Energy Services (TSX:PHX) reported a net profit margin of 7.6%, down from last year’s 13.5%. A notable one-off gain of CA$25.9 million shaped this period’s results. Revenues are projected to grow at 2.3% per year, which is slower than the Canadian market average of 5.1%. However, earnings are set to rise at an impressive 30.8% annually, far outpacing the market’s 12.1% forecast. In a market where value and growth rarely align, PHX’s combination of strong expected earnings growth and...
NYSE:CTVA
NYSE:CTVAChemicals

Corteva (CTVA) Profit Margin Surge Reinforces Bullish Narratives Despite Slower Growth Forecasts

Corteva (CTVA) posted a sharp turnaround in profitability this quarter, with net profit margins reaching 8.6% compared to last year’s 5.2%, and EPS outcome reflecting 68.1% growth over the past twelve months. Despite this rebound, forward-looking forecasts show earnings expected to grow at 12.1% per year and revenue at 2.7% per year, both trailing wider US market growth expectations. The current share price of $63.67 still sits below an internal fair value estimate of $94.37. Investors are...
NYSE:AFL
NYSE:AFLInsurance

Aflac (AFL) Margin Miss Challenges Bullish Outlook Despite Discount to Fair Value

Aflac (AFL) reported a net profit margin of 15.3%, down from 28.3% last year, as the company continued to face downward pressure on earnings. Over the past five years, EPS has declined by 4% annually, but the outlook is for earnings to grow at 9.2% per year going forward, with revenue expected to rise 1.9% per year, both of which lag the broader US market averages. Against this backdrop, investors will weigh Aflac’s compressed margins and history of earnings decline against steady forecasts...